Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
Phase IIa study in COPD patients aimed to evaluate the safety, tolerability ,pharmacodynamics
(effect on biological markers of inflammation in induced sputum and in blood, and on
pulmonary function) and on pharmacokinetics of CHF 6001 (a PDE4 inhibitor) after 28-days of
daily inhaled dosing.